IDEXX has acquired CoVet, an artificial intelligence–powered clinical documentation and workflow platform serving veterinary practices, marking the exit of Chicago Pacific Founders Pet Fund from the venture-backed company. The transaction was announced September 30, 2026, according to a deal report published by SaasRise. Financial details of the purchase weren't made public, but the deal was structured as an outright sale with no earn-out provisions or conditional payments disclosed.
The Hamilton-based CoVet operates across North America and Europe, automating charting tasks for veterinary clinics through AI-driven scribing technology. IDEXX, a global animal health diagnostics company, now takes full ownership of CoVet's technology stack and existing customer base, closing the startup's current financing round. Chicago Pacific Foundersreceives cash proceeds from the sale, ending its position in the venture. The combined entity plans a 12-month rollout to integrate CoVet's platform into IDEXX's existing practice-management software suite, with an emphasis on seamless technical connectivity.
The report states that CoVet's natural-language processing models can cut charting time by up to 40 percent, a measure that improves practice efficiency and enhances data quality for analytics downstream. The purchase reflects IDEXX's push to broaden its software portfolio beyond diagnostics into AI-enhanced practice management, aiming to reduce clinician burnout and strengthen data capture. IDEXX also signaled plans to develop additional machine-learning features—including predictive health alerts and automated billing workflows—using CoVet's underlying models.
The acquisition positions IDEXX to capture a larger portion of the veterinary SaaS market, which industry analysts say is growing at double-digit annual rates, according to the report. Veterinary clinics have increasingly adopted software to manage appointments, billing, and records, but manual documentation remains a persistent bottleneck that CoVet's AI platform directly addresses. For CoVet, the IDEXX tie-up offers access to a wider distribution network, tighter integration with diagnostic hardware, and capital to speed European expansion where distribution challenges previously limited growth. The report notes that the deal is part of a wider pattern in which established health-tech firms acquire specialized AI startups to build end-to-end service offerings.
IDEXX customers will gain a unified workflow merging diagnostic data with automated charting, likely boosting platform retention and creating opportunities to upsell advanced analytics modules, the report finds. Competitors including Vetsource and Covetrus may need to accelerate their own AI roadmaps to match the integrated capabilities IDEXX now commands. The transaction also signals to early-stage investors that niche AI players addressing workflow pain points in vertical SaaS sectors can be absorbed into larger platforms at attractive valuations, which could shape future fundraising dynamics in veterinary technology. As IDEXX deploys CoVet's tools across its installed base, the combined operation may establish a new standard for comprehensive practice management solutions, spurring rivals to pursue similar acquisitions or internal AI development. Investors and operators should watch whether the integration delivers measurable gains in efficiency and retention that justify scaling AI-driven automation across other health-tech verticals, where manual workflows continue to constrain productivity and practitioner satisfaction.